CS
TSHA icon

Credit Suisse’s Taysha Gene Therapies TSHA Stock Holding History

Credit Suisse’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-12
Closed – – 4297
2022
Q2 		$0 Sell
12
-15,189
-100% -$60.3K ﹤0.01% 4321
2022
Q1 		$99K Buy
15,201
+445
+3% +$3.33K ﹤0.01% 3474
2021
Q4 		$172K Buy
14,756
+1,304
+10% +$19.7K ﹤0.01% 4310
2021
Q3 		$249K Buy
13,452
+63
+0.5% +$1.2K ﹤0.01% 4155
2021
Q2 		$283K Buy
+13,389
New +$309K ﹤0.01% 4136

Other funds holding TSHA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Credit Suisse's TSHA Position: Q3 2022 in Review

Credit Suisse sold out of Taysha Gene Therapies (TSHA) in Q3 2022, closing a stake of 12 shares.

Credit Suisse first reported a position in TSHA in Q2 2021 and held it in 5 quarters. The position peaked at $283K in Q2 2021. 54 funds tracked by Wall St. Rank hold TSHA as of Q3 2022.

  • Credit Suisse reported no remaining Taysha Gene Therapies position as of Q3 2022 after selling out during the quarter.
  • Credit Suisse sold 12 Taysha Gene Therapies shares in Q3 2022.
  • Credit Suisse first reported a position in Taysha Gene Therapies in Q2 2021 and held it in 5 quarters.
  • Credit Suisse's Taysha Gene Therapies position peaked at $283K in Q2 2021.
  • 54 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q3 2022.

Based on Credit Suisse's 13F filing for Q3 2022, filed 10 Nov 2022.